


RIQAS

RANDEX INTERNATIONAL QUALITY ASSESSMENT SCHEME



**ENROLMENT DOCUMENT
THERAPEUTIC DRUGS PROGRAMME
RQ9111**

This document must be completed and returned to RIQAS

RIQAS

THERAPEUTIC DRUGS PROGRAMME

RQ9111

Lab. Reference Number

Please tick the correct option:

This is a new registration for Therapeutic Drugs

☐

This is an update to an existing Therapeutic Drugs registration

☐

If you wish to register multiple instruments, please complete separate enrolment documents for each instrument

On each document please state an instrument identification name here

Instrument Group Reports

Instrument group reports can be provided on request. Please contact RIQAS or your local Randox office or distributor for more details.

Inter-Laboratory Group Reports

To receive inter-laboratory group reports, please contact RIQAS directly.

Please indicate cycles required in boxes below

Cycle 70 March 2024 - August 2024 ☐

Cycle 71 September 2024 - February 2025 ☐

Cycle 72 March 2025 - August 2025 ☐

Cycle 73 September 2025 - February 2026 ☐

Primary Contact Details: (CAPITAL LETTERS ONLY)

QA Officer

Laboratory / Hospital Name

Department

Postal Address

City

State

Postal / Zip Code

Country

Telephone Number

Randox Office / Distributor

RIQAS THERAPEUTIC DRUGS PROGRAMME

RIQASNet - ELECTRONIC CORRESPONDENCE

Participation on RIQAS requires access to RIQASNet, a web-based online method for result entry, viewing of released reports and addition or change of assay details. In addition, PDF reports can be e-mailed to up to 3 e-mail addresses. Internet access and login details are required for RIQASNet. A login will be supplied by RIQAS based on "e-mail address 1" below. It is also possible to receive a csv file containing the information found on the summary page of the routine report.

I wish to receive a summary csv file ☐
(csv files must be sent to the same email addresses as the PDF reports)

FOR RIQAS USE ONLY

RIQASNet No

Date added:

By:

PDF copies set to

csv copies set to

Primary Contact email for RIQASNet/PDF reports/summary csv files (Please write in capital letters only)

E-mail address 1:

E-mail addresses for additional PDF reports/summary csv files

E-mail address 2:

E-mail address 3:

Customer Declaration: By submitting this enrolment document to RIQAS, either directly or via my local Randox representative, I, (the customer of RIQAS) confirm that:

- 1) I have read and understood the RIQAS policies stated in the most recent Method Questionnaire associated with this programme.
- 2) I understand that the submission of this enrolment document to RIQAS marks the beginning of an on-going agreement, and I will be automatically enrolled in subsequent cycles of this programme until RIQAS receives written confirmation of my cancellation. This should be received by RIQAS 12 weeks prior to the month in which the cycle starts.
- 3) I understand that I must inform RIQAS of any changes to my contact details, assay details or contract status
- 4) I authorise Randox Laboratories Ltd. to send communication related to the products and service provided to the e-mail or postal addresses stated on this document
- 5) I understand that I am permitted to request disclosure of, change or erase personal details held by Randox Laboratories Ltd. at any time.

REGISTRATION OF ASSAY DETAILS

It is possible to inform RIQAS of your chosen parameters and assay details by

- 1) Completing the 'REGISTRATION OF ASSAY DETAILS' on the following pages **OR**
- 2) Adding your own assay details using RIQASNet

Please select one of the following options

☐

I wish to add my own assay details via RIQASNet once I have received my username, password and Lab Reference Number from RIQAS

(You do not need to complete the 'REGISTRATION OF ASSAY DETAILS' section of this document)

☐

I wish to inform RIQAS of my assay details using this enrolment document

(please complete all remaining pages of the 'REGISTRATION OF ASSAY DETAILS' section)

For any further queries, please contact your local Randox office, Sales Representative or RIQAS directly.

THIS PROGRAMME IS ACCREDITED BY
UKAS TO ISO/IEC 17043:2010

Please contact RIQAS at

Tel:

+44 (0) 28 9445 4399

E-Mail:

mail@riqas.com

RIQAS Scheme Co-ordinator: Sally Picton

RANDOX LABORATORIES LTD., 55 Diamond Road, Crumlin, County Antrim, BT29 4QY, United Kingdom



0010

RIQAS THERAPEUTIC DRUGS PROGRAMME

REGISTRATION OF ASSAY DETAILS

ONLY COMPLETE THIS SECTION IF YOU DO NOT INTEND TO REGISTER
YOUR METHODS VIA RIQASNET

Please indicate your requirements by ✓ or by writing in the boxes below.
Current participants should complete the document only for method changes.
Please state 2-digit Vitros Slide Generation Numbers where appropriate.

ANALYTE	METHOD CODE	INSTRUMENT	REAGENT	SI UNITS	✓	OTHER UNITS
AMIKACIN	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	µmol/l	<input style="width: 20px;" type="checkbox"/>	<input style="width: 100%;" type="text"/>
CAFFEINE	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	µmol/l	<input style="width: 20px;" type="checkbox"/>	<input style="width: 100%;" type="text"/>
CARBAMAZEPINE	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	µmol/l	<input style="width: 20px;" type="checkbox"/>	<input style="width: 100%;" type="text"/>
	VITROS SLIDE GENERATION NO.	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>			
CICLOSPORIN	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	nmol/l	<input style="width: 20px;" type="checkbox"/>	<input style="width: 100%;" type="text"/>
DIGOXIN	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	nmol/l	<input style="width: 20px;" type="checkbox"/>	<input style="width: 100%;" type="text"/>
	VITROS SLIDE GENERATION NO.	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>			
ETHOSUXIMIDE	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	µmol/l	<input style="width: 20px;" type="checkbox"/>	<input style="width: 100%;" type="text"/>
GENTAMICIN	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	µmol/l	<input style="width: 20px;" type="checkbox"/>	<input style="width: 100%;" type="text"/>
LITHIUM	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	mmol/l	<input style="width: 20px;" type="checkbox"/>	<input style="width: 100%;" type="text"/>
OR						
LITHIUM (VITROS)	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	mmol/l	<input style="width: 20px;" type="checkbox"/>	<input style="width: 100%;" type="text"/>
	VITROS SLIDE GENERATION NO.	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>			
METHOTREXATE	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	µmol/l	<input style="width: 20px;" type="checkbox"/>	<input style="width: 100%;" type="text"/>
PARACETAMOL	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	mmol/l	<input style="width: 20px;" type="checkbox"/>	<input style="width: 100%;" type="text"/>
(ACETAMINOPHEN)	VITROS SLIDE GENERATION NO.	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>			
PHENOBARBITAL	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	µmol/l	<input style="width: 20px;" type="checkbox"/>	<input style="width: 100%;" type="text"/>
	VITROS SLIDE GENERATION NO.	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>			
PHENYTOIN	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	µmol/l	<input style="width: 20px;" type="checkbox"/>	<input style="width: 100%;" type="text"/>
	VITROS SLIDE GENERATION NO.	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>			
PRIMIDONE	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	µmol/l	<input style="width: 20px;" type="checkbox"/>	<input style="width: 100%;" type="text"/>
SALICYLIC ACID	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	mmol/l	<input style="width: 20px;" type="checkbox"/>	<input style="width: 100%;" type="text"/>
	VITROS SLIDE GENERATION NO.	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>			
THEOPHYLLINE	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	µmol/l	<input style="width: 20px;" type="checkbox"/>	<input style="width: 100%;" type="text"/>
	VITROS SLIDE GENERATION NO.	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>			
TOBRAMYCIN	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	µmol/l	<input style="width: 20px;" type="checkbox"/>	<input style="width: 100%;" type="text"/>
VALPROIC ACID	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	µmol/l	<input style="width: 20px;" type="checkbox"/>	<input style="width: 100%;" type="text"/>
VANCOMYCIN	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	µmol/l	<input style="width: 20px;" type="checkbox"/>	<input style="width: 100%;" type="text"/>

Please use this space to describe "other" methods, instruments and reagents.